Crémieux
Crémieux
ADA-3,44 %
Eli Lilly just showed that you can lose tons of fat while barely losing any muscle using their activin type-II receptor inhibitor, bimagrumab. We are approaching a golden era of weight loss, where everyone can easily be muscular and skinny. Prepare for hordes of hot Americans.
Gallery 1
The semaglutide-only weight loss results also speak against the lie that GLP-1RAs cause excess lean mass loss, as the proportion lost was comparable to typical non-GLP-1RA weight loss. To learn more, check out the update I just made on this article:
Reporting on this result from the ADA 2025 conference:
Egan Peltan
Egan Peltan
Can less weight loss be better weight loss? This morning at ADA, Eli Lilly released data on the Believe Phase 2b study of Bimagrumab in combination with a GLP-1 (Semaglutide) The goal: lose only fat Approach: anorectic + anabolic
@subtlechemism Nope.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@cmoncanes There's never been good evidence for them. It just doesn't gomd up on closer inspection.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@AnnieTyzak Eye issues? Never supported with strong evidence.
Crémieux
Crémieux
A new study of NAION risk with GLP-1RAs just came out. With semaglutide, there was not only no apparent risk, but if anything, there was reduced risk.
Gallery 1
@elonmusk And it seems like consumers will have options, too. Multiple other companies are close to their own versions of this product: We live in amazing times!
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
@AZchilly Then I'd say you didn't read the article. Here's a helpful thread with human rather than non-human primate results.
Crémieux
Crémieux
More companies are jumping in to improve GLP-1-driven weight loss. Scholar Rock is now reporting their own results from using combination tirzepatide and a myostatin inhibitor. At 24 weeks, their results are comparable to semaglutide at 26 weeks with Regeneron's inhibitor:
Gallery 1
Quelle:twitter
8.115
0
Der Inhalt dieser Seite wird von Drittparteien bereitgestellt. Sofern nicht anders angegeben, ist OKX nicht der Autor der zitierten Artikel und erhebt keinen Anspruch auf das Urheberrecht an den Materialien. Die Inhalte dienen ausschließlich zu Informationszwecken und spiegeln nicht die Ansichten von OKX wider. Sie stellen keine Form der Empfehlung dar und sind weder als Anlageberatung noch als Aufforderung zum Kauf oder Verkauf digitaler Assets zu verstehen. Soweit generative KI zur Bereitstellung von Zusammenfassungen oder anderen Informationen eingesetzt wird, kann der dadurch erzeugte Inhalt ungenau oder widersprüchlich sein. Mehr Infos findest du im verlinkten Artikel. OKX haftet nicht für Inhalte, die auf Drittpartei-Websites gehostet werden. Digitale Assets, einschließlich Stablecoins und NFT, bergen ein hohes Risiko und können stark schwanken. Du solltest sorgfältig überlegen, ob der Handel mit oder das Halten von digitalen Assets angesichts deiner finanziellen Situation für dich geeignet ist.